Physician profile
Robert Parise
NPI 1144608571
$3,637.63
in general payments reported to CMS, 2019-2025
13 companies · $46.45 in 2025
The $46.45 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2020: $109 · 2021: $1,415 · 2022: $937 · 2023: $1,021 · 2025: $46.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,062 · Education: $4.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,062.21 |
| Education | $4.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $743.38 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $726.16 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Alkermes, INC. | $651.30 | 2020-2023 | Aristada, Lybalvi, Vivitrol |
| Janssen Pharmaceuticals, INC | $412.31 | 2021-2023 | Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $346.08 | 2020-2023 | Caplyta |
| Lundbeck LLC | $247.88 | 2020-2023 | Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $207.09 | 2021-2023 | Ingrezza |
| Indivior INC. | $162.54 | 2022-2023 | Perseris |
| Sunovion Pharmaceuticals INC. | $61.87 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $30.40 | 2021-2022 | |
| Axsome Therapeutics, INC. | $20.28 | 2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $17.15 | 2021 | |
| Noven Therapeutics, LLC | $11.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Parise listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.